Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations

Aligos Therapeutics, Inc. (ALGS)

1.31   -0.03 (-2.24%) 06-26 19:18
Open: 1.38 Pre. Close: 1.34
High: 1.38 Low: 1.28
Volume: 1,903,595 Market Cap: 56(M)
Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. Its lead drug candidate is ALG-010133, a s-antigen transport-inhibiting oligonucleotide polymer that is in Phase Ib clinical trial for the treatment of chronic hepatitis B (CHB); and ALG-000184, a capsid assembly modulator, which is in Phase I clinical trials to treat CHB. The company also develops ALG-020572, an antisense oligonucleotide to prevent HBsAg translation and secretion; and ALG-055009, a small molecule THR-ß agonist that is in the Phase 1a/1b for the treatment of non-alcoholic steatohepatitis(NASH). In addition, it develops siRNA drug candidate, ALG-125755, as well as ALG-125097 and ALG-125819, demonstrated potent inhibition of HBsAg release from HBV-infected cells. It has entered into license and collaboration agreements with Luxna Biotech Co., Ltd. to develop and commercialize products containing oligonucleotides targeting hepatitis B virus genome; Emory University to provide hepatitis B virus capsid assembly modulator technology; research, licensing, and commercialization agreement with Katholieke Universiteit Leuven to develop coronavirus protease inhibitors; and Merck to discover, research, optimize, and develop oligonucleotides directed against a NASH. The company was incorporated in 2018 and is headquartered in South San Francisco, California.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 1.38 - 1.39 1.39 - 1.39
Low: 1.26 - 1.27 1.27 - 1.28
Close: 1.3 - 1.31 1.31 - 1.32

Technical analysis

as of: 2022-06-24 4:37:56 PM
Overall:       
Stoxline posted a BUY today, same as yesterday. Upward movement continues.
Target: Six months: 1.65     One year: 1.92
Support: Support1: 1.02    Support2: 0.85
Resistance: Resistance1: 1.41    Resistance2: 1.64
Pivot: 1.32
Moving Average: MA(5): 1.23     MA(20): 1.3
MA(100): 1.82     MA(250): 8.9
MACD: MACD(12,26): -0.1     Signal(9): -0.1
Stochastic oscillator: %K(14,3): 32.7     %D(3): 23
RSI: RSI(14): 51.1
52-week: High: 18.23  Low: 1.02
Average Vol(K): 3-Month: 358 (K)  10-Days: 410 (K)

Price, moving averages and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ ALGS ] has closed above bottom band by 47.3%. Bollinger Bands are 14% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Headline News

Sun, 26 Jun 2022
How to watch the ALGS Championship 2022 - Upcomer

Fri, 24 Jun 2022
Do Analysts Expect Aligos Therapeutics Inc (ALGS) Stock to Rise After It Is Up 12.61% in a Month? - InvestorsObserver

Fri, 24 Jun 2022
Mirum Pharmaceuticals (MIRM) Highlights Data Demonstrating Impact of LIVMARLI - StreetInsider.com

Thu, 16 Jun 2022
Apex pros with COVID may be barred from playing in ALGS Championship, players say - Dot Esports

Tue, 14 Jun 2022
Monitoring Nutrition and Progression of ALGS - MD Magazine

Tue, 14 Jun 2022
Using Maralixibat for the Management of Pediatric ALGS - MD Magazine

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 0 (M)
Shares Float 40 (M)
% Held by Insiders 1.824e+007 (%)
% Held by Institutions 16.5 (%)
Shares Short 2,410 (K)
Shares Short P.Month 0 (K)

Stock Financials

EPS -1.3318e+008
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin (%) 0
Operating Margin (%) -2
Return on Assets (ttm) 261.4
Return on Equity (ttm) -38.3
Qtrly Rev. Growth 6.02e+006
Gross Profit (p.s.) 0
Sales Per Share 0.1
EBITDA (p.s.) -3.08
Qtrly Earnings Growth -3.4
Operating Cash Flow 0 (M)
Levered Free Cash Flow -106 (M)

Stock Valuations

PE Ratio -0.01
PEG Ratio 0
Price to Book value 0
Price to Sales 12.97
Price to Cash Flow 0

Stock Dividends

Dividend 0
Forward Dividend 2.9e+006
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
7 Binary Options
Your Ad Here
android_stock_chart
StockChart iOS
stoxline_lite
StoxlineLite iOS
stoxline_pro
StoxlineLite iOS
Option_Calculator
OptionCalc iOS
android_stock_chart
StockChart Android
stoxline_lite
StoxlineLite Android
stoxline_pro
StoxlinePro Android
Option_Calculator
OptionCalc Android
(c) 2006-2022 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.